| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| R&D Expense | $49.2M | — | +60.8% |
| SG&A Expense | $8.8M | — | +106.0% |
| Operating Income | -$58.0M | — | -66.3% |
| Net Income | -$53.1M | — | -74.7% |
| EPS (Basic) | -$0.52 | — | -44.4% |
| EPS (Diluted) | -$0.52 | — | -44.4% |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Cash & Equivalents | $52.5M | +8.8% | +3.8% |
| Short-term Investments | $452.8M | -0.9% | +32.4% |
| Current Assets | $513.2M | -0.4% | +29.4% |
| Total Assets | $530.6M | -0.5% | +29.5% |
| Current Liabilities | $47.2M | -8.9% | +81.0% |
| Total Liabilities | $50.2M |
| Line Item | 2026-03-31 | Q/Q | Y/Y |
|---|---|---|---|
| Operating Cash Flow | -$46.0M | — | -4.6% |
| Investing Cash Flow | $4.5M | — | +110.0% |
| Financing Cash Flow | $45.7M | — | — |
| +91.6% |
| Stockholders' Equity | $480.5M | +0.4% | +25.3% |